Clinical Trial: Comparison of Complarate® (Tocilizumab Biosimilar) and Actemra® in Patients With Rheumatoid Arthritis
Study Status: COMPLETED
Recruit Status: COMPLETED
Condition: Rheumatoid Arthritis
Study Type: INTERVENTIONAL
Official Title: Double-blind Multicenter Randomized Study of the Effectiveness and Safety of Tocilizumab Biosimilar (Complarate®) and Actemra® in Parallel Groups in Patients With Rheumatoid Arthritis With Repeated In
Brief Summary:
This is a randomized double-blind comparative parallel group study of the efficacy and safety of tocilizumab biosimilar Complarate® and Actemra® in the treatment of patients with rheumatoid arthritis with moderate to high disease activity.Participants received an intravenous dose of tocilizumab 8 mg/kg once 4 weeks.The time on study treatment was 24 weeks.
Read more